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Abstract
Background: Diabetic cardiomyopathy (DCM) is a disorder of the heart muscle in people with diabetes, which is
characterized by both systolic and diastolic dysfunction. The effective treatment strategy for DCM has not been
developed.
Methods: Rats were divided into 3 groups with different treatment. The control group was only injected with
citrate buffer (n = 8). The diabetes group and diabetes treated group were injected with streptozotocin to induce
diabetes. After success of diabetes induction, the rats with diabetes were treated with (diabetes treated group, n =
8) or without (diabetes group, n = 8) recombinant human Neuregulin-1 (rhNRG-1). All studies were carried out 16
weeks after induction of diabetes. Cardiac catheterization was performed to evaluate the cardiac function.
Apoptotic cells were determined by TUNEL staining. Left ventricular (LV) sections were stained with Masson to
investigate myocardial collagen contents. Related gene expressions were analyzed by quantitative real-time PCR
(qRT-PCR).
Results: Diabetes impaired cardiac function manifested by reduced LV systolic pressure (LVSP), maximum rate of
LV pressure rise and fall (+dp/dt max and -dp/dt max) and increased LV end-diastolic pressure (LVEDP). The rhNRG-
1 treatment could significantly alleviate these symptoms and improve heart function. More TUNEL staining positive
cells were observed in the diabetic group than that in the control group, and the rhNRG-1 treatment decreased
apoptotic cells number. Furthermore, qRT-PCR assay demonstrated that rhNRG-1 treatment could decrease the
expression of bax and caspase-3 and increase that of bcl-2. Collagen volume fraction was higher in the diabetic
group than in the control group. Fibrotic and fibrotic related mRNA (type I and type III collagen) levels in the
myocardium were significantly reduced by administration of rhNRG-1.
Conclusion: rhNRG-1 could significantly improve the heart function and reverse the cardiac remodeling of DCM
rats with chronic heart failure. These results support the clinical possibility of applying rhNRG-1 as an optional
therapeutic strategy for DCM treatment in the future.
Background
Patients with diabetes often develop atherosclerosis and
hypertension, both of which are major risk factors to
the development of heart disease. However, cardiomyo-
pathy can also be developed in the absence of these
established risk factors [1,2]. In the past decades, many
studies provided evidences for a specific cardiomyopathy
in diabetes (diabetic cardiomyopathy, DCM), which may
contribute to myocardial dys f u n c t i o ni nt h ea b s e n c eo f
coronary artery atheroma [3]. DCM is characterized by
both systolic and diastolic dysfunction because of
reduced contractility, prolonged relaxation, and
decreased compliance of the myocardium [4,5]. Patholo-
gical mechanism of DCM may be due to myocardial
apoptosis and necrosis, reactive hypertrophy, and inter-
mediary fibrosis, structural and functional changes of
the small coronary vessels, disturbance of the manage-
ment of the metabolic cardiovascular load, and cardiac
autonomic neuropathy [6]. As so far, there is still no
effective treatment strategy for DCM.
Neuregulin-1 (NRG-1) is a widely expressed signaling
molecule that is involved in cell differentiation,
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encoded by a large gene (1400 Kb) located in chromo-
some 8p12, with several promoters and alternative spli-
cing isoforms [7,8]. In adult heart, at least three
different NRG-1a isoforms and eight NRG-1b isoforms
are expressed. In particular, the b isoform of NRG-1 is
highly expressed in the heart and 10 to 100 times more
bioactive. NRG-1 expression seems to be restricted to
the endothelial cells near cardiomyocytes (in the endo-
cardium and in the myocardial microvasculature),
because it is absent in larger coronary arteries, veins and
aorta [9]. Hedhli et al. demonstrated that endothelial-
derived NRG plays an important role in cardiac myocyte
protection against ischemic injury in the heart [10].
Recently, studies using recombinant human neuregulin-
1 (rhNRG-1) containing the epidermal growth factor
(EGF)-like domain (necessary for ErbB2/ErbB4 activa-
tion) demonstrated that NRG-1 plays an important role
in heart performance [11,12]. We hypothesized that
NRG-1 could improve cardiac function of diabetic rats,
probably by regulating cardiac apoptosis and fibrosis,
Streptozotocin (STZ)-induced diabetes (Type I) model is
well established for investigating DCM in small animals.
Therefore, we decided to explore hemodynamic and
physiopathological responses to recombinant human
NRG-1 (beta isoform, rhNRG-1) in rat DCM model
induced by STZ.
Materials and methods
Animals and procedures
Experiments were performed in compliance with the
ARRIVE guidelines on animal research[13]. Sprague-
Dawley (SD) rats at postnatal age of 6 weeks (body
weight 200-220 g, Animal center of Nanchang Univer-
sity, Nanchang, China) were assigned to control group
(n = 8) and diabetic group (n = 20). Diabetes was
induced by intraperitoneal injection of streptozotocin
(50 mg/kg; Sigma Chemical, France) [14,15]. Tail vein
blood glucose was measured every 3 days in the first
week and those with plasma glucose levels ≥16.7 mmol/
L were considered to be diabetic. Control rats were
injected i.p. with 1 ml/kg body weight of 20 mmol/L
citrate buffer (pH 4.5) vehicle at the same time and con-
tinued to be raised on standard food and water for the
whole experiment period. Twelve weeks after induction
of diabetes, 16 diabetic rats remained in the experiment
(the rest 4 rats died or ruled out for unsuccessful dia-
betic induction), which were randomly assigned to the
following 2 groups: diabetic rats (citrate buffer injected
by tail vein every 2 days during the next 2 weeks, n =
8), and diabetic rats treated with rhNRG-1 (10 μg/kg
injected by tail vein every 2 day during the next 2
weeks, n = 8; Novartis Pharmaceutical, Switzerland).
The rats were kept on standard food and water for
another 2 weeks. All studies were carried out 16 weeks
after induction of diabetes.
Analysis of myocardial function
To evaluate the cardiac function, cardiac catheterization
was performed as previously described [16]. Briefly, after
the induction of light general anesthesia (anesthetized
with 4% chloral hydrate solution (1 ml/100 g) by intra-
peritoneal injection), one catheter was inserted into the
right carotid artery and advanced into the left ventricle
(LV). Ventricular pressure signals were measured with a
transducer and conditioner (AD instruments MLT0830,
Australia) and digitally recorded with a data acquisition
system (Power lab, AD instruments, Australia). The fol-
lowing indices were obtained: heart rate (HR), LV systolic
pressure (LVSP), LV end-diastolic pressure (LVEDP), and
maximum rate of LV pressure rise and fall (+dp/dt max
and -dp/dt max). During the process, animals were
placed on controlled heating pads. Core temperature was
measured via a rectal probe and was maintained at 37°C
[17]. Rats were terminated after analysis of myocardial
function. The hearts were harvested for the next studies.
Histopathological process and detection of apoptotic cells
by TUNEL staining
Samples were fixed in 10% formalin and paraffin
embedded in the surgical pathology facility of Nanchang
University. Terminal deoxynucleotidyl transferase-
mediated dUTP nick end labeling (TUNEL) analysis was
performed with a commercially available kit according to
the manufacturer’s instructions (Promega, America). Slides
were counter stained with hematoxylin (blue). Three mid-
ventricular sections (from the apex to the base) of each
heart were analyzed. Cardiomyocyte nuclei were quantified
by counting randomly 10 fields per section. The apoptotic
index (percentage of apoptotic nuclei) was calculated as
apoptotic nuclei/total nuclei counted ×100%.
Analysis of myocardial collagen content
LV sections were stained with Masson to measure inter-
stitial fibrosis. Interstitial collagen was quantified at a
final magnification of 200× with a microscope (Olympus
BX51, America) connected to a video camera (Nikon
DS-Fi1, Japan). Photographs obtained under microscopy
were used to calculate the collagen volume fraction of
the myocardial interstitium by computer imaging analy-
sis system (MPIAS 500, Japan). The content of intersti-
tial collagen (expressed as the fractional area of the
entire cross-section) was averaged on nine fields selected
across the wall thickness in the septum and free wall.
Gene expression analysis by real-time quantitative RT-PCR
Tissue samples obtained from the left ventricle free wall
were minced. RNA was extracted as reported before [18].
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Page 2 of 8Total RNA was extracted with Trizol reagent according to
the guideline of manufacture (Invitrogen, America) from
the samples. For RT-PCR, cDNA was synthesized in a 20
μl reaction volume containing 4 μgo ft o t a lR N Aa n d
Superscript II RT (Fermentas, Canada), according to the
instructions of the manufacturer. Real time PCR was car-
ried out using 7500 Real Time PCR System (Applied Bio-
systems, America), using SYBR Green I (Applied
Biosystems, America) as fluorescence dye according to the
manufacturer’s instructions. Relative quantitation of
mRNA expression in the gene of interest was calculated
using the comparative threshold cycle number for each
sample. To control the variation in the amount of DNA,
gene expression of the target sequence was normalized in
relation to the expression of an internal control, b-actin.
Primers for collagen type, collagen type III, bcl-2, bax, cas-
pase-3 and b-actin were listed as follows:
collagen type I F: 5’- GTTCGTGGTTCTCAGGGTAG
-3’;
collagen type I R: 5’- TTGTCGTAGCAGGGTTCTTT
-3’;
collagen type III F: 5’- TGCCCACAGCCTTCTA-
CACCCT -3’;
collagen type III R: 5’- CAGCCATTCCTCCCACTC-
CAG -3’;
bcl-2 F: 5’- CGGGAGATCGTGATGAAGT -3’;
bcl-2 R: 5’- CCACCGAACTCAAAGAAGG -3’;
bax F: 5’- GCAGGGAGGATGGCTGGGGAGA -3’;
bax R: 5’- TCCAGACAAGCAGCCGCTCACG -3’;
caspase-3 F: 5’-AGTCTGACTGGAAAGCCGAA -3’;
caspase-3 R: 5’- CGGGATCTGTTTCTTTGCAT -3’;
b-actin F: 5’- TGTGCTATGTTGCCCTAGACTTC
-3’;
b-actin R: 5’-CGGACTCATCGTACTCCTGCT -3’.
Statistical analysis
All data were presented as mean ± SEM. Comparisons
between groups were made by one-way analysis of var-
iance (ANOVA) with Fisher protected least significant
differences post hoc comparison. Results were consid-
ered statistically significant if p < 0.05.
Results
NRG-1 improved myocardial function
Sixteen weeks after induction of diabetes, rat cardiac
function was evaluated by invasive hemodynamic
measurements. There was no significant difference in
heart rate among the three groups. The lower LVSP and
higher LVEDP were observed in diabetic group than
that in control group. Resting maximum rates of rise
(+dp/dt max) and fall (-dp/dt max) in LV pressure were
also impaired after induction of diabetes, indicating that
the diabetic rat systolic and diastolic functions were sig-
nificantly impaired. After the administration of rhNRG-
1, the hemodynamic abnormalities mentioned above
were remarkably attenuated (Table 1).
NRG-1 protected cardiomyocytes against apoptosis
TUNEL assay was performed to examine the apoptosis
in vivo. The numbers of TUNEL staining positive cells
in the diabetic group were higher than that in the con-
trol groups (Figure 1). The rhNRG-1 treatment resulted
in significantly less apoptotic cells than untreated group.
Quantitative real-time PCR was used to determine the
mRNA expression of bcl-2, bax, and capase-3, which are
regarded as the markers of apoptosis. It was showed
that bcl-2 was down regulated but bax and capase-3
were up regulated in the diabetic group, whereas,
rhNRG-1 alleviated the changes (Figure 2, 3). Since bcl-
2 is known for anti-apoptosis, and bax and caspase-3
pro-apoptosis, these results indicate that rhNRG-1 treat-
ment could protect cardiomyocytes against apoptosis.
NRG-1 attenuated myocardial interstitial fibrosis
The collagen volume fraction, which is an indicator of
interstitial fibrosis, was higher in the diabetic group
than in the control group (Figure 4). Similarly, the type
I and type III collagen mRNA expression levels were
also significantly up regulated in the diabetic group (Fig-
ure 5). These fibrotic and fibrotic related genes over-
expression in the myocardium was remarkably inhibited
by the administration of rhNRG-1, suggesting that
rhNRG-1 treatment could attenuate myocardial intersti-
tial fibrosis caused by diabetes.
Discussion
Our data suggests a fresh optional strategy for DCM
treatment. Through our studies with rhNRG-1 in DCM
rats, we found that the administration of NRG-1 could
improve cardiac function and reversed remodeling of
t h eh e a r to fD C Mr a t sb yr e g ulating cardiomyocytes
apoptosis and cardiac fibrosis. The data also further
Table 1 Hemodynamic parameters evaluated by invasive measurements.
Group HR
(beats/min)
LVSP
(mm Hg)
LVEDP
(mm Hg)
dp/dt
(mm Hg/s)
-dp/dt
(mm Hg/s)
Control (n = 8) 347 ± 38 131 ± 18 2.1 ± 0.8 6423 ± 417 5723 ± 331
Diabetes(n = 8) 312 ± 29 101 ± 9* 11.4 ± 3.3* 5396 ± 325* 4321 ± 289*
NRG-1(n = 8) 323 ± 32 118 ± 13
# 6.9 ± 2.4*
# 5850 ± 387*
# 4728 ± 302*
#
Values are presented as mean ± SEM; HR: heart rate; LVSP: left ventricle systolic pressure; LVEDP: left ventricle end diastolic pressure; +dp/dt: maximum rate of
left ventricle pressure rise; -dp/dt: maximum rate of left ventricle pressure fall; * P ≤ 0.05 vs. control group;
# P < 0.05 vs. Diabetic group.
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Page 3 of 8supports the hypothesis that NRG-1 plays an important
role in regulating heart function.
NRG-1 acts as a paracrine factor via the ErbB family
of tyrosine kinase receptors expressed in cardiomyo-
cytes. The ErbB-receptors are a family of four
transmembrane receptors that bind multiple growth
factors, including epidermal growth factor (EGF),
transforming growth factor-a (TGF-a), and NRG1-4.
ErbB3 is expressed in prenatal myocytes, whereas,
adult ventricular myocytes express only ErbB1, ErbB2,
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Figure 1 Analysis of cardiomyocytes apoptosis. Cardiomyocytes apoptosis detected by TUNEL method. (A) TUNEL staining pictures, in which
brown stained cells were TUNEL positive cells, which were defined as “apoptotic”. Magnification at 400×, scale bar is 100 μm. (B) Statistical
analysis of Cardiomyocytes apoptosis. TUNEL positive cells were increased in Diabetes, and decreased by NRG-1 (n = 8, * P < 0.05 vs. control
group; # P < 0.05 vs. Diabetic group.)
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Page 4 of 8and ErbB4. It is known that ErbB1, also known as the
EGF-receptor, does not bind NRG-1, so only ErbB2
and -4 do serve as NRG-1’s receptors in adult cardio-
myocytes [19,20]. NRG-1 acts through ErbB2 and
ErbB4 in a paracrine fashion to stimulate MEK/ERK,
Akt/PI3-kinase, Src/FAK, and NO synthase, which
together promote myocyte function and survival in the
setting of cardiac stress [21-24]. Recently, hNRG-1 was
successfully used to improve the preservation of rodent
heart. The functional improvement was accompanied
by increase phosphorylation of Akt, ERK, STAT3 and
GSK- 3b[25]. NRG-1 stimulates activation of MEK/
ERK with subsequent induction of protein synthesis
and hypertrophic gene expression. Another down-
stream signaling pathway is the Akt/PI3-kinase path-
way which appears to be involved in the protection of
cardiac myocytes against cell death, as well as regula-
tion of metabolism and growth. NRG-1 induces PI3-
kinase dependent activation of Akt in cardiac myo-
cytes, a pathway that has been heavily implicated in
cell survival [26,27]. Interestingly, Akt-GSK-3b path-
way has been shown to be important in mediating the
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Figure 2 Statistical analysis of the expression of apoptosis related mRNA detected by PCR. Compared with Control group, the mRNA
expression of Bax was increased and Bcl-2 was decreased in diabetic group, while NRG-1 increased Bcl-2 mRNA expression and decreased Bax
mRNA expression when compared with un-treated (Diabetic) group. (n = 8, * P < 0.05 vs. control group; # P < 0.05 vs. Diabetic group.)
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Figure 3 Statistical analysis of the expression of caspase-3 mRNA detected by PCR. Compared with Control group, the mRNA expression
of caspase-3 was increased in diabetic group, while NRG-1 decreased caspase-3 mRNA expression when compared with un-treated (Diabetic)
group. (n = 8, * P < 0.05 vs. control group; # P < 0.05 vs. Diabetic group.)
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Page 5 of 8cardioprotective effects of tanshione IIA on STZ
induced diabetic cadiomyopathy in rats [6]. Increased
cardiomyocyte apoptosis has been described in hearts
of diabetic mice and patients, and hypothesized as an
important mechanism of DCM [28]. Our results
suggest that anti-apoptosis effect may contribute to
myocardial protection of NRG-1[6].
DCM is considered as interstitial and perivascular
fibrosis. It was known that myocardial fibrosis could
cause myocardial dysfunctioni nd i a b e t e s .O u rf i n d i n g s
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Figure 4 Analysis of interstitial fibrosis. (A) Fibrotic infiltration in the myocardium with Masson’s trichrome staining. Area stained blue
represent fibrotic infiltration. Magnification at 200×, scale bar is 100 μm. (B) Quantitative analysis of fibrosis. The collagen volume fraction was
higher in the diabetic group than in the control group, while NRG-1 attenuated such increase. (n = 8, * P < 0.05 vs. control group; # P < 0.05 vs.
Diabetic group.)
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Page 6 of 8also showed that NGR-1 attenuated heart fibrosis. The
precise mechanism was unclear. Recent study showed
that TGF-b could contribute fibrosis by binding to ErbB-
receptors [29]. Enhancements of NRG-1 may compete
with TGF-b by binding to ErbB-receptors to lessen the
fibrosis triggered through the TGF-ErbB signal pathway.
NO synthase, which can be stimulated by NRG-1/ErbB
signal pathway, may also be involved in myocardial fibro-
sis. It was reported that NO synthase could attenuate
myocardial fibrosis by regulating renin release [30]. Up-
regulation of the renin-angiotensin system (RAS) has
been described in diabetes and is associated with devel-
opment of cardiac hypertrophy and fibrosis. In addition,
cardiomyocytes and endothelial cells in the hearts of indi-
viduals with diabetes and end-stage heart failure manifest
evidence of oxidative stress, apoptosis, and necrosis that
correlate with RAS activation [2]. In the present study, it
is highly possible that some part of the actions NRG-1
inhibiting cardiac remodeling is through the regulation of
rein release through NO synthase.
It was reported that NRG-1/ErbB expression declined
in the later stages when pump failure occurred [31],
The decline in NRG-1 expression coincided with the
development of eccentric ventricular hypertrophy and
pump failure and was accompanied by a down regula-
tion in the mRNA levels of ErbB2 and ErbB4. Presum-
ably, it is due to the increased levels of angiotensin II
and epinephrine, both of which reduce NRG-1 mRNA
synthesis in cardiac endothelium [32]. The replenish-
ment of NRG-1 may inhibit the physiopathological
aggravation of DCM.
Conclusion
The heart function of DCM rats with chronic heart fail-
u r ew a ss i g n i f i c a n t l yi m p r o v e db yN R G - 1 ,s u p p o r t i n g
the rationale of replenishing NRG-1 as an optional
selection for DCM therapy, although further clinical stu-
dies are required. rhNRG-1 seems to be able to protect
cardiomyocytes against apoptosis and reduce the extent
of myocardial interstitial fibrosis. The exact mechanism
will be pursued in the future studies.
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Figure 5 Statistical analysis of the expression of collagen type I (A) and type III (B) mRNA by PCR. Compared with Control group, the
mRNA expression of collagen type I and type III was increased in diabetic group, while NRG-1 suppressed such induction of collagen type I and
type III mRNA. (n = 8, * P < 0.05 vs. control group; # P < 0.05 vs. Diabetic group.)
Li et al. Cardiovascular Diabetology 2011, 10:69
http://www.cardiab.com/content/10/1/69
Page 7 of 8Received: 12 July 2011 Accepted: 29 July 2011 Published: 29 July 2011
References
1. Emerging Risk Factors Collaboration, Sarwar N, Gao P, Seshasai SR, Gobin R,
Kaptoge S, Di Angelantonio E, Ingelsson E, Lawlor DA, Selvin E, Stampfer M,
Stehouwer CD, Lewington S, Pennells L, Thompson A, Sattar N, White IR,
Ray KK, Danesh J: Diabetes mellitus, fasting blood glucose concentration,
and risk of vascular disease: a collaborative meta-analysis of 102
prospective studies. Lancet 2010, 375:2215-2222.
2. Battiprolu PK, Gillette TG, Wang ZV, Lavandero S, Hill JA: Diabetic
cardiomyopathy: mechanisms and therapeutic targets. Drug Discov Today
Dis Mech 2010, 7:e135-e143.
3. Fisher BM, Gillen G, Lindop GB, Dargie HJ, Frier BM: Cardiac function and
coronary arteriography in asymptomatic type-1 (insulin-dependent)
diabetic patients: evidence for a specific diabetic heart disease.
Diabetologia 1986, 29:706-712.
4. An D, Rodrigues B: Role of changes in cardiac metabolism in
development of diabetic cardiomyopathy. Am J Physiol Heart Circ Physiol
2006, 291:H1489-1506.
5. Boudina S, Abel ED: Diabetic cardiomyopathy revisited. Circulation 2007,
115:3213-3223.
6. Sun D, Shen M, Li J, Li W, Zhang Y, Zhao L, Zhang Z, Yuan Y, Wang H,
Cao F: Cardioprotective effects of tanshinone IIA pretreatment via kinin
B2 receptor-Akt-GSK-3β dependent pathway in experimental diabetic
cardiomyopathy. Cardiovasc Diabetol 2011, 10:4.
7. Chen MS, Bermingham-McDonogh O, Danehy FT Jr, Nolan C, Scherer SS,
Lucas J, Gwynne D, Marchionni MA: Expression of multiple neuregulin
transcripts in postnatal rat brains. J Comp Neurol 1994, 349:389-400.
8. Pentassuglia L, Sawyer DB: The Role of Neuregulin 1β/ErbB signaling in
the heart. Exp Cell Res 2009, 315:627-637.
9. Lemmens K, Segers VF, Demolder M, De Keulenaer GW: Role of
neuregulin-1/ERBB2 signaling in endothelium-cardiomyocyte cross-talk. J
Biol Chem 2006, 281:19469-19477.
10. Hedhli N, Huang Q, Kalinowski A, Palmeri M, Hu X, Russell RR, Russell KS:
Endothelium-derived neuregulin protects the heart against ischemic
injury. Circulation 2011, 123:2254-2262.
11. Jabbour A, Hayward CS, Keogh AM, Kotlyar E, McCrohon JA, England JF,
Amor R, Liu X, Li XY, Zhou MD, Graham RM, Macdonald PS: Parenteral
administration of recombinant human neuregulin-1 to patients with
stable chronic heart failure produces favourable acute and chronic
haemodynamic responses. Eur J Heart Fail 2011, 13:83-92.
12. Gu X, Liu X, Xu D, Li X, Yan M, Qi Y, Yan W, Wang W, Pan J, Xu Y, Xi B,
Cheng L, Jia J, Wang K, Ge J, Zhou M: Cardiac functional improvement in
rats with myocardial infarction by up-regulating cardiac myosin light
chain kinase with neuregulin. Cardiovasc Res 2010, 88:334-343.
13. Kilkenny C, Browne WJ, Cuthill IC, Emerson M, Altman DG: Improving
bioscience research reporting: the ARRIVE guidelines for reporting
animal research. PLoS Biol 2010, 8:e1000412.
14. Gurney AM, Howarth FC: Effects of streptozotocin-induced diabetes on
the pharmacology of rat conduit and resistance intrapulmonary arteries.
Cardiovasc Diabetol 2009, 8:4.
15. Reinking BE, Wedemeyer EW, Weiss RM, Segar JL, Scholz TD:
Cardiomyopathy in offspring of diabetic rats is associated with
activation of the MAPK and apoptotic pathways. Cardiovasc Diabetol
2009, 8:43.
16. Wichi R, Malfitano C, Rosa K, De Souza SB, Salemi V, Mostarda C, De
Angelis K, Irigoyen MC: Noninvasive and invasive evaluation of cardiac
dysfunction in experimental diabetes in rodents. Cardiovascular
Diabetology 2007, 6:14.
17. Veal N, Moal F, Wang J, Vuillemin E, Oberti F, Roy E, Kaassis M, Trouvé R,
Saumet JL, Calès P: New method of cardiac output measurement using
ultrasound velocity dilution in rats. J Appl Physiol 2001, 91:1274-1282.
18. Li B, Zeng Q, Wang H, Shao S, Mao X, Zhang F, Li S, Guo Z: Adipose tissue
stromal cells transplantation in rats of acute myocardial infarction.
Coronary Artery Disease 2007, 18:221-227.
19. Holbro T, Hynes NE: Erbb receptors: Directing key signaling networks
throughout life. Annu Rev Pharmacol Toxicol 2004, 44:195-217.
20. Dammann O, Bueter W, Leviton A, Gressens P, Dammann CE: Neuregulin-1:
a potential endogenous protector in perinatal brain white matter
damage. Neonatology 2008, 93:182-187.
21. Kuramochi Y, Guo X, Sawyer DB: Neuregulin activates erbB2-dependent
src/FAK signaling and cytoskeletal remodeling in isolated adult rat
cardiac myocytes. J Mol Cell Cardiol 2006, 41:228-235.
22. Hertig CM, Kubalak SW, Wang Y, Chien KR: Synergistic roles of neuregulin-
1 and insulin-like growth factor-I in activation of the
phosphatidylinositol 3-kinase pathway and cardiac chamber
morphogenesis. J Biol Chem 1999, 274:37362-37369.
23. Ky B, Kimmel SE, Safa RN, Putt ME, Sweitzer NK, Fang JC, Sawyer DB,
Cappola TP: Neuregulin-1 beta is associated with disease severity and
adverse outcomes in chronic heart failure. Circulation 2009, 120:310-317.
24. Calvo M, Zhu N, Grist J, Ma Z, Loeb JA, Bennett DL: Following nerve injury
neuregulin-1 drives microglial proliferation and neuropathic pain via the
MEK/ERK pathway. Glia 2011, 59:554-568.
25. Jabbour A, Gao L, Kwan J, Watson A, Sun L, Qiu MR, Liu X, Zhou MD,
Graham RM, Hicks M, MacDonald PS: A recombinant human neuregulin-1
peptide improves preservation of the rodent heart after prolonged
hypothermic storage. Transplantation 2011, 91:961-967.
26. Baliga RR, Pimental DR, Zhao YY, Simmons WW, Marchionni MA, Sawyer DB,
Kelly RA: NRG-1-induced cardiomyocyte hypertrophy. Role of PI-3-kinase,
p70(S6K), and MEK-MAPK-RSK. Am J Physiol 1999, 277:H2026-2037.
27. Fukazawa R, Miller TA, Kuramochi Y, Frantz S, Kim YD, Marchionni MA,
Kelly RA, Sawyer DB: Neuregulin-1 protects ventricular myocytes from
anthracycline-induced apoptosis via erbB4-dependent activation of PI3-
kinase/Akt. J Mol Cell Cardiol 2003, 35:1473-1479.
28. Boudina S, Abel ED: Diabetic cardiomyopathy, causes and effects. Rev
Endocr Metab Disord 2010, 11:31-39.
29. Andrianifahanana M, Wilkes MC, Repellin CE, Edens M, Kottom TJ,
Rahimi RA, Leof EB: ERBB receptor activation is required for profibrotic
responses to transforming growth factor beta. Cancer Res 2010,
70:7421-7430.
30. Chatziantoniou C, Pauti MD, Pinet F, Promeneur D, Dussaule JC, Ardaillou R:
Regulation of renin release is impaired after nitric oxide inhibition.
Kidney Int 1996, 49:626-633.
31. Rohrbach S, Niemann B, Silber RE, Holtz J: Neuregulin receptors erbB2 and
erbB4 in failing human myocardium: depressed expression and
attenuated activation. Basic Res Cardiol 2005, 100:240-249.
32. Lemmens K, Doggen K, De Keulenaer GW: Role of neuregulin-1/ErbB
signaling in cardiovascular physiology and disease: implications for
therapy of heart failure. Circulation 2007, 116:954-960.
doi:10.1186/1475-2840-10-69
Cite this article as: Li et al.: Therapeutic effects of neuregulin-1 in
diabetic cardiomyopathy rats. Cardiovascular Diabetology 2011 10:69.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Li et al. Cardiovascular Diabetology 2011, 10:69
http://www.cardiab.com/content/10/1/69
Page 8 of 8